Leerink Partners' affiliate, MEDACorp, announced today the launch of a new division, the Center for Pharmacoeconomics (CPE), which will be dedicated to advancing the understanding of the societal ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Notable insider trades include GOOD JENNIFER L, President & CEO at Trevi Therapeutics Inc (TRVI), who sold 40277 shares on Sep 05 ’24, at $3.11 each, totaling $0.13 million. On May 29 ’24, SCIASCIA ...

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...

Shares of the company were down about 3.9% after the bell. The Arizona-based company posted third-quarter revenue of $977.9 million, down 4.9% sequentially, missing estimates of $987.34 million, ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...

Veracyte (NASDAQ:VCYT – Free Report) had its price objective upped by Leerink Partners from $35.00 to $40.00 in a research report report published on Thursday morning, Benzinga reports.

Natera (NASDAQ:NTRA – Free Report) had its price objective hoisted by Leerink Partners from $140.00 to $150.00 in a report issued on Thursday, Benzinga reports. Leerink Partners currently has an ...

Leerink Partners has maintained its Market Perform rating and $4.00 price target for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX). The firm acknowledged the encouraging new HELIOS open-label data ...

Leerink Partners has maintained its Market Perform rating and $4.00 price target for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX). The firm acknowledged the encouraging new HELIOS open-label data for ...

On Thursday, Leerink Partners maintained its Outperform rating and $990.00 price target on shares of pharmaceutical giant Eli Lilly (NYSE:LLY). The firm's stance comes in light of recent ...